(888) 552-6760 SCHEDULE AN APPOINTMENT

Kevin G. Chan,

Urologic Surgeon, Head, Reconstructive Urology

Biography photo
Location
City of Hope Duarte
1500 East Duarte Road
Duarte, CA 91010
Specialties
Urology and Urologic Oncology
Education
Medical school:
Degrees
  • 1998, M.D., University of Southern California Medical Center, Los Angeles, CA

  • 1994, B.S., Biology, magna cum laude, University of California Los Angeles, Los Angeles, CA

Residency
  • 2004, Residency in Urology, Los Angeles County + University of Southern California Medical Center, Los Angeles, CA

Internship
  • 1999, Los Angeles County + University of Southern California Medical Center, Los Angeles, CA, Internship in General Surgery

Professional Experience
  • 2023-present, Clinical Professor, Division of Urology and Urologic Oncology, Department of Surgery, City of Hope, Duarte, CA

  • 2014-2023, Associate Clinical Professor, Division of Urology and Urologic Oncology, Department of Surgery, City of Hope, Duarte, CA

  • 2012-present, Head, Reconstructive Urology, City of Hope, Duarte, CA

  • 2004-2014, Assistant Clinical Professor, Division of Urology and Urologic Oncology, Department of Surgery, City of Hope, Duarte, CA

Academic Appointments
  • Clinical Professor, Division of Urology and Urologic Oncology, Department of Surgery
About Me
Urologic surgeon Kevin Chan, M.D., joined City of Hope's Division of Urology and Urologic Oncology in 2004, where he focuses on urinary tract reconstruction in the treatment of various urologic cancers including bladder cancer, prostate cancer and upper tract urothelial carcinoma. He also treats the complications of urologic cancer treatments including urinary incontinence and erectile dysfunction. Additionally, Dr. Chan treats all aspects of general urology, including benign prostatic hyperplasia and kidney stones.
 
At City of Hope, Dr. Chan has established one of the country's largest programs in continent urinary diversion using robot-assisted laparoscopic radical cystectomy for the treatment of bladder cancer. He currently serves on the National Comprehensive Cancer Network Guidelines Committee for Bladder Cancer and Penile Cancer. He helped lead the International Pasadena Consensus Panel that established best practice recommendations in robot-assisted radical cystectomy and urinary diversion. He has been invited to demonstrate his surgical techniques in Asia and Europe.
 
In addition to clinical practice, Dr. Chan conducts research in surgical techniques and postoperative pathways that help minimize complications and improve outcomes in the treatment of bladder cancer. He has pioneered the use of fluorescence imaging to evaluate ureteral blood perfusion to significantly lower complication rates in urinary diversion for bladder cancer. He has vast experience in the surgical treatment of male urinary incontinence, which is usually the result of prostate and bladder surgery. He has established a large database at City of Hope with the goal of improving surgical techniques used to treat male urinary incontinence. Dr. Chan's research interests also include the development of novel diagnostic modalities utilized to predict responsiveness of bladder cancer after treatment with chemotherapy and immunotherapy.
 
Dr. Chan earned his Bachelor of Science degree, magna cum laude, in biology at University of California, Los Angeles. He is a member of Phi Beta Kappa honor society. Dr. Chan earned his medical degree at University of Southern California School of Medicine in 1998. He completed his urology training at University of Southern California under the mentorship of Donald Skinner, M.D. Dr. Chan has received a number of honors and awards, including the Society of Laparoendoscopic Surgeons Outstanding Laparoendoscopic Resident Award and the Pfizer Scholar in Urology Award. He has been awarded the City of Hope Urologic Oncology and Robotic Surgery Fellowship Faculty Educator of the Year multiple years.
Patient ratings
Star ratings and comments are only available for medical, radiation and gynecologic oncologists. Gynecologic surgical offerings are not included at this time due to a different survey tool required to evaluate these services. CTCA uses a validated Press Ganey® survey, which captures patient experience feedback for the primary oncology services of chemotherapy and radiation therapy at our comprehensive care and research centers. Following industry best practice, star ratings and comments are only published for physicians with a minimum of 30 completed patient surveys.